SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00

by adminAdrianRamirez | May 17, 2017 | Axim Biotechnologies, Canchew, Press Releases

SAN DIEGO, May 17, 2017 — Medical Marijuana, Inc. (OTC PINK:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) received coverage...

AXIM Biotech Clinical Study to Develop Bioequivalent Product to Marinol Listed on Clinicaltrials.gov

by adminAdrianRamirez | May 16, 2017 | Axim Biotechnologies, Press Releases

NEW YORK, May 15, 2017 –– AXIM® Biotechnologies, Inc. (AXIM® Biotech) AXIM, +37.64% a world leader in cannabinoid research and development, today announced that information on the company’s Bioavailability Study on Dronabinol in a controlled-release, functional...

Medical Marijuana, Inc. Major Investment AXIM Biotech Moves Forward With Development Of MedChew Rx Pharmaceutical Chewing Gum

by adminAdrianRamirez | May 3, 2017 | Axim Biotechnologies, Press Releases

SAN DIEGO, May 3, 2017 — Medical Marijuana, Inc. (MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc.’s (AXIM® Biotech) (AXIM) product development...

Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Term Sheet Agreement With U.S. API Company To Develop Bioequivalent Product To Marinol

by adminAdrianRamirez | Mar 28, 2017 | Axim Biotechnologies, Press Releases

[vc_row][vc_column][vc_column_text]SAN DIEGO, March 28, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech)...

AXIM Biotechnologies Partners with Ora, Inc. for Cannabinoid-Based Drug Development and Clinical Trials for Eye Conditions

by adminAdrianRamirez | Mar 23, 2017 | Axim Biotechnologies, Press Releases, Scientific Research

In order to fast-track approval of its new products, AXIM® Biotechnologies, Inc., a Medical Marijuana, Inc. investment company, has retained the services of Ora®, Inc. for the development of its cannabinoid-based eye treatments.   A global Contract Research...